Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analysis of ovarian cancer cells after drug administration and tRNA transfection at 10 and 24 hours

ABSTRACT: SLFN11 sensitizes cancer cells to DNA-damaging agents (DDAs) by cleaving and reducing tRNALeu(TAA). In this study, we investigated how the reduction of tRNALeu(TAA) contributes to cell death under Camptothecin (CPT) treatment. RNA-seq and proteome analyses were performed to assess the global effects of tRNALeu(TAA) transfection. The results suggest that tRNALeu(TAA) influences the expression of proteins essential for proteostasis, particularly those involved in ubiquitin-dependent proteolysis, at the protein level rather than the mRNA level. These findings indicate that SLFN11 plays a crucial role in proteostasis by regulating tRNAs, and thus determines cell fate under DDA treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE303192 | GEO | 2025/07/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Proteomics comparison of ovarian cancer cells with drug administration and tRNA transfection (24 hours)

Project description:Quantitative proteome analyses of ovarian cancer cells (TOV-112D cells) in the following three conditions were carried out. 1: Treatment with transfection reagent followed by treatment with DMSO 2: Treatment with transfection reagent followed by treatment with 100nM Camptothecin 3: Treatment with transfection reagent and 10nM tRNALeu(TAA) followed by treatment with 100nM Camptothecin

2025-07-26 | PXD066104 | JPOST Repository

Proteomics comparison of ovarian cancer cells with drug administration and tRNA transfection

Project description:Quantitative proteome analyses of ovarian cancer cells (TOV-112D cells) in the following three conditions were carried out. 1: Treatment with transfection reagent for 4 hours followed by treatment with DMSO 2: Treatment with transfection reagent for 4 hours followed by treatment with 100nM Camptothecin 3: Treatment with transfection reagent and 10nM tRNALeu(TAA) for 4 hours followed by treatment with 100nM Camptothecin

2025-05-22 | PXD052458 | JPOST Repository

Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death [tRNA seq]

Project description:Velcrin compounds kill cancer cells expressing high levels of phosphodiesterase 3A (PDE3A) and Schlafen family member 12 (SLFN12) by inducing complex formation between these two proteins, but the mechanism of cancer cell killing by the PDE3A–SLFN12 complex is not fully understood. Here, we report that the physiological substrate of SLFN12 RNase is tRNALeu(TAA). SLFN12 selectively digests tRNALeu(TAA), and velcrin treatment promotes the cleavage of tRNALeu(TAA) by inducing PDE3A–SLFN12 complex formation in vitro. We found that distinct sequences in the variable loop and acceptor stem of tRNALeu(TAA) are required for substrate digestion. Velcrin treatment of sensitive cells results in downregulation of tRNALeu(TAA), ribosome pausing at Leu-TTA codons and global inhibition of protein synthesis. Velcrin-induced cleavage of tRNALeu(TAA) by SLFN12 and the concomitant global inhibition of protein synthesis thus define a new mechanism of apoptosis initiation.

2022-09-01 | GSE185827 | GEO

Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death [Ribo-Seq]

2022-09-01 | GSE185826 | GEO

Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death [RNA-Seq]

2022-09-01 | GSE185822 | GEO

SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to 1 replicative stress caused by DNA damaging agents

Project description:Schlafen family member 11 (SLFN11) increases sensitivity to replicative stress and has been proposed as a biomarker to predict sensitivity to DNA damaging agents (DDA). However, the role of SLFN11 in pediatric cancer has not been well explored. In this study, we found that protein expression strongly correlated with response to the PARP inhibitor talazoparib and the topoisomerase I inhibitor irinotecan in sarcoma cell lines, with SLFN11 knockout resulting in significant loss of sensitivity in vitro and in vivo. However, in contrast to its activity in adult tumors, high SLFN11 expression did not correlate with favorable outcome in a retrospective study of children with sarcoma. Our work suggests that the potential of SLFN11 to act as a biomarker may be limited to certain tumor backgrounds or contexts, and that impaired apoptotic response may be one targetable mechanism of resistance to DDA-induced replicative stress

2022-04-08 | GSE181094 | GEO

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer

Project description:Large independent analyses on cancer cell lines followed by functional studies have identified Schlafen 11 (SLFN11), a putative helicase, as the strongest predictor of sensitivity to DNA-damaging agents (DDA), including platinum. However, its role as a prognostic biomarker is undefined, partially due to the lack of validated methods to score SLFN11 in human tissues. Here, we implemented a pipeline to quantify SLFN11 in human cancer samples. By analyzing a cohort of high-grade serous ovarian carcinoma (HGSOC) specimens prior platinum-based chemotherapy treatment, we show, for the first time, that SLFN11 density in both the neoplastic and microenvironmental components was independently associated with favorable outcome. We observed SLFN11 expression in both infiltrating innate and adaptive immune cells, and analyses in a second, independent, cohort revealed that SLFN11 is associated with immune activation in HGSOC. We found that platinum treatments activated immune-related pathways in ovarian cancer cells in a SLFN11-dependent manner, representative of tumor-immune transactivation. Moreover, SLFN11 expression was induced in activated, isolated, immune cell subpopulations, hinting that SLFN11 in the immune compartment may be an indicator of immune transactivation. In summary, we propose SLFN11 is a dual biomarker capturing simultaneously interconnected immunological and cancer-cell-intrinsic functional dispositions associated with sensitivity to DDA treatment.

2021-07-13 | GSE179896 | GEO

Snd1-Mtdh interaction regulates cell survival under camptothecin-induced replication stress

Project description:PyMT tumor cells with indicated status of Mtdh and Snd1 were treated with camptothecin (CPT) and the transcirptome profiles were determined and compared two sets of experiments: (1) vector control vs Snd1-KD under CPT treament (2) PyMT/Mtdh-KO cells reconstituted with either WT or Snd1-binding deficient mutant Mtdh (W391D) under CPT treatment

2014-08-12 | E-GEOD-55522 | biostudies-arrayexpress

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress [RNA-seq_CPT]

Project description:Schlafen 11 (SLFN11) has recently arisen as a novel cellular restriction factor against replication stress. Here we show that SLFN11 increases chromatin accessibility genome-wide, dominantly at promoters in response to replication stress induced by the CHK1 inhibitor prexasertib and the topoisomerase I inhibitor, camptothecin. Concomitantly SLFN11 selectively activates cellular stress response pathways by inducing the transcription of the Immediate Early Genes (IEGs) including JUN, FOS, EGR1, NFKB2 and ATF3. Both chromatin opening and IEG activation require the putative helicase activity of SLFN11 whereas extrinsic IEG activation by serum induction is SLFN11-independent. SLFN11-dependent IEG activation is also observed across 55 non-isogenic NCI-60 cell lines by comparing transcriptome data before and after camptothecin treatment. We conclude that SLFN11 acts as a global regulator of chromatin structure and an intrinsic IEG activator with the potential to engage the native immune activation in response to replicative stress.

2020-01-17 | GSE140937 | GEO

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress [RNA-seq_CHK1i]

2020-01-17 | GSE140936 | GEO